Inhibition of gene expression by antisense oligonucleotides relies on the ability of an ODN to bind a complementary messenger RNA sequence and prevent translation of the mRNA. Most human follicular B cell lymphomas are associated with t(14;18) chromosome translocation that joins the bcl-2 gene with the 1gH locus. This hybrid gene causes upregulation of the BCL-2 protein expression, endowing cells with survival advantage. The capacity of oligonucleotides to modulate gene expression specifically has been exploited to down regulate the overexpression of BCL-2 protein in the SU-DHL-4 human follicular B cell lymphoma line by targeting the hybrid transcript with ODN encompassing the unique nucleotide sequence in the fusion region.

Synthetic antisense oligonucleotides: Principles and antileukemic activity / S. Morelli, A. Quattrone, N. Schiavone, A.L. Calastretti, A.T. Bevilacqua, S. Tomasini, A.N. Nicolin. - In: ONCOLOGY REPORTS. - ISSN 1021-335X. - 4:suppl. 1(1997), pp. 219-225. ((Intervento presentato al 43. convegno Course of the International School of Pharmacology - Genetic and Immunochemotherapeutic Approaches in Cancer Treatment tenutosi a Erice nel 1996.

Synthetic antisense oligonucleotides: Principles and antileukemic activity

A. Quattrone;A.L. Calastretti;A.T. Bevilacqua;A.N. Nicolin
1997

Abstract

Inhibition of gene expression by antisense oligonucleotides relies on the ability of an ODN to bind a complementary messenger RNA sequence and prevent translation of the mRNA. Most human follicular B cell lymphomas are associated with t(14;18) chromosome translocation that joins the bcl-2 gene with the 1gH locus. This hybrid gene causes upregulation of the BCL-2 protein expression, endowing cells with survival advantage. The capacity of oligonucleotides to modulate gene expression specifically has been exploited to down regulate the overexpression of BCL-2 protein in the SU-DHL-4 human follicular B cell lymphoma line by targeting the hybrid transcript with ODN encompassing the unique nucleotide sequence in the fusion region.
Antileukemic acitivity; Antisense oligonucleotides; Cancer Research; Oncology
Settore BIO/14 - Farmacologia
Settore BIO/13 - Biologia Applicata
1997
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/528868
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact